Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Aurobindo Pharma generic Altace capsules
Aurobindo Pharma‘s Ramipril capsules USP 1.25mg, 2.5mg, 5mg and 10mg are generic equivalent to King Pharmaceuticals’ Altace capsules 1.25mg, 2.5mg, 5mg and 10mg. Altace capsules are indicated as
Aurobindo Pharma‘s Ramipril capsules USP 1.25mg, 2.5mg, 5mg and 10mg are generic equivalent to King Pharmaceuticals’ Altace capsules 1.25mg, 2.5mg, 5mg and 10mg. Altace capsules are indicated as
The agreement allows for the joint development and licensing of early stage compounds from Lilly to Synthes for use within orthopedic trauma, spine, craniomaxillofacial and reconstructive areas. The
The biotechnology firm’s Neo-Urinary Conduit is indicated as a treatment for bladder dysfunction requiring incontinent urinary diversion. Orphan drug designation offers Tengion seven years of US marketing exclusivity
The settlement would include both the US DOJ and the Attorneys General of many of the US, in resolution of two False Claims Act qui tam actions initiated
Vascazen is a medical food to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating EPA and DHA Omega-3 Fatty acids. Pivotal Therapeutics will
Nova23041, a formulation for the treatment of dry eye symptoms, is a preservative-free oil-in-water emulsion resulting from Novasorb patented technology. Novagali claims the Novasorb’s technological platform enables the
Sonepcizumab is the drug substance included in company’s two lead compounds – iSONEP and ASONEP. Sonepcizumab is an antibody that binds to and inhibits sphingosine-1-phosphate (S1P), a bioactive
Under a research agreement signed between the two parties, JDRF is responsible to give milestone-based financial help to Selecta with an aim to use Selecta’s technology for the
Currently, the company is evaluating the safety, tolerability and immunogenicity of NuThrax also known as AV7909, which is in a Phase 1b trial. According to the company, the
The 12 weeks data showed positive results demonstrating an increase in ‘on’ time and decrease in ‘off’ time without troublesome dyskinesias. Abbott said the primary efficacy endpoint is